TransMedics (TMDX) is a publicly traded Healthcare sector company. As of August 26, 2026, TMDX trades at $92.87 with a market cap of $3.25B and a P/E ratio of 21.02. TMDX moved +0.00% today. Year to date, TMDX is -23.71%; over the trailing twelve months it is -18.59%. Its 52-week range spans $55.00 to $156.00. Analyst consensus is buy with an average price target of $94.22. Rallies surfaces TMDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for TMDX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $92.87 |
| Market Cap | $3.25B |
| P/E Ratio | 21.02 |
| EPS | $4.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $156.00 |
| 52-Week Low | $55.00 |
| Volume | 6.46K |
| Avg Volume | 0 |
| Revenue (TTM) | $668.47M |
| Net Income | $151.70M |
| Gross Margin | 58.69% |
10 analysts cover TMDX: 0 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $94.22.